Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy
Journal
Hepatology
Journal Volume
50
Journal Issue
2
Pages
654-655
Date Issued
2009
Author(s)
Abstract
Immunosuppresive therapy, including steroids, cytotoxic agents, and tumor necrosis factor‐α antagonists, is the cornerstone of treatment for patients with moderate‐to‐severe inflammatory bowel disease.1 The case reported by Zeitz et al.2 reiterated hepatitis B virus (HBV) reactivation as a potentially life‐threatening complication in patients who received immunosuppressive therapy and the necessity of preventive antiviral therapy, consistent with our observation.3 Several issues should be addressed to optimize the preventive strategy in this setting.
SDGs
Other Subjects
entecavir; hepatitis B surface antigen; immunosuppressive agent; lamivudine; rituximab; tenofovir; antiviral therapy; hepatitis B; Hepatitis B virus; high risk patient; human; immune system; immunocompetence; immunosuppressive treatment; letter; lymphoma; priority journal; remission; side effect; toxic hepatitis; treatment duration; virus mutation; virus reactivation; chemically induced disorder; hepatitis B; recurrent disease; Hepatitis B; Humans; Immunosuppressive Agents; Recurrence
Publisher
John Wiley and Sons Ltd
Type
letter